MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
November 17, 2022
Ryan Allway November 17th, 2022 News, Top News – Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor accepted for presentation – BALTIMORE, November 17, 2022–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious... Read more
Cardiol Therarpeutics Receives FDA Approval For Investigational New Drug (IND) Application For Phase II/III COVID-19 Trial
CBD September 25, 2020
Ryan Allway September 25th, 2020 News, Top News Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD) Oakville, Ontario–(Newsfile Corp. – September 25, 2020) – Cardiol... Read more
Cannabidiol Phase 1 Clinical Trial Launches, Targeting Inflammatory Heart Condition
CBD September 17, 2020
Robin Lefferts September 17th, 2020 Cannabidiol, or CBD, is thought to be beneficial for a wide variety of ailments, ranging from poor sleep to pain to PTSD and beyond. To this point, however, there haven’t been many clinical trials conducted to thoroughly prove or disprove the benefits of CBD.... Read more
Ryan Allway March 30th, 2020 Uncategorized The COVID-19 outbreak has become a major source of stress over the past several weeks. In addition to the fear and anxiety of disease, quarantines and “stay at home” orders have contributed to stress levels, leading to poor sleep, unhealthy eating, and other... Read more
Ryan Allway December 6th, 2019 App, Exclusive, News, Top Story Cannabidiol, better known as CBD, has become one of the most popular wellness products in the United States over the past couple of years. BDS Analytics and Arcview Market Research expect CBD sales to grow at a 49% compound... Read more
Joy Crosby August 9th, 2019 App, Exclusive, News, Top Story As an emerging and relatively new line of business, cannabis has already proven itself to be a powerhouse of a market. The global cannabis industry’s revenue ballooned to US $12.2 billion in 2018, with predictions that it will reach... Read more
Ryan Allway August 2nd, 2019 Exclusive, News, Top Story, Uncategorized Only days after announcing that its wholly owned subsidiary was awarded a German cannabis and cultivation and extraction licence, XPhyto Therapeutics is ready to enter the public domain. With a final prospectus filed with the British Columbia Securities Commission,... Read more
Ryan Allway August 1st, 2019 App, Exclusive, News, Top Story The cannabis industry is quickly moving through a well-known cycle for emerging markets. Like Google in the tech industry, early market entrants that have become successful in a given subset of the fragmented market are starting to look to... Read more
Synthetic Cannabinoids: The New Age of Medical Marijuana
July 22, 2019
Ryan Allway July 22nd, 2019 App, Exclusive, News, Top News Believe it or not, the world’s first blockbuster drug is still one of the most commonly used today. Acetylsalicylic acid, better known as Aspirin®, is a synthetic derivative of the natural substance salicylic acid, an extract from the bark... Read more
Ryan Allway July 10th, 2019 App, Exclusive, News, Top News The last six weeks have seen major strides taken by The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF) (Frankfurt:YG3) to maintain their position as an exciting, forward-thinking and innovative cannabis company. An organisation dedicated to disrupting the wellness industry with revolutionary... Read more
